Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton

✍ Scribed by Sol Epstein

• Publisher: American Society for Bone and Mineral Research
• Year: 2009
• Tongue: English
• Weight: 682 KB
• Volume: 11
• Category: Article
• ISSN: 0884-0431
• DOI: 10.1002/jbmr.5650110102

✦ Synopsis

III 111 M \ N I ) ioi< organ transplantation is growing tre-T mendously, fueled hy the long-term survival of organ recipients. the absence o f alternative treatment strategies, and the enhanced effectiveness of immunosuppressant q c n t s t o prevent organ rejection. Indeed the survival of organ transplant recipients has been positively transformed hy the introduction o f cyclosporinc as a therapeutic agent, despite the side effects o f this drug which ;ire severe and inclutlc osteopenia. This review will describe the commonly prcseriild drugx iiscd to prevent organ rejection and the av;iiliihlc cviclcncc regarding whether they influence the skeleton. Such information is presently poorly appreciated and often disregarded when judging the potential v:iluc of :I tr;inspl;int procedure.

GLUCOCORTICOIDS

Al t hough gl ucocor t icoids are ii ni ong t he most corn nion clriigs used as triple o r combined therapy to prevent o r treat organ rejection. the harnifiil clinical effects of this drug on All~c 1-1 F3 n at c i 11 M c d ica I ( 'en t er. PI1 ilade I ph iii . Pen nay Ivan ia. Ll , S . A